Dr. Rogers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
555 S 18th St
Ste 4C
Columbus, OH 43205Phone+1 614-224-6222Fax+1 614-241-5232
Education & Training
Indiana University School of MedicineResidency, Ophthalmology, 2003 - 2006- Indiana University School of Medicine/Methodist HospitalInternship, Transitional Year, 2002 - 2003
Wright State University Boonshoft School of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2007 - 2026
IN State Medical License 2003 - 2007- American Board of Ophthalmology Ophthalmology
Clinical Trials
- Bevacizumab Treatment For Type 1 ROP Start of enrollment: 2022 May 18
Roles: Contact
Publications & Presentations
PubMed
- 39 citationsShort-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity.David K. Wallace, Raymond T. Kraker, Sharon F. Freedman, Eric R. Crouch, Amit R. Bhatt
JAMA Ophthalmology. 2020-06-01 - 93 citationsAssessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing StudyDavid K. Wallace, Raymond T. Kraker, Sharon F. Freedman, Eric R. Crouch, Amy K. Hutchinson
JAMA Ophthalmology. 2017-06-01 - 12 citationsLow- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.Sharon F Freedman, Amra Hercinovic, David K Wallace, Raymond T Kraker, Zhuokai Li
Ophthalmology. 2022-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
